The global Rare NRG1 fusion market is expected to surpass an impressive valuation of US$ 9.49 Billion in 2023 and is projected to reach US$ 20 Billion by 2033, with a CAGR of 7.73%.
Oncogenic fusions of NRG1 may cause excess accumulation of the NRG1-fusion protein at the cell surface. This causes persistent activation of ErbB receptor tyrosine kinases that drive excess activity in the mTOR and MAPK pathways and promote tumorigenesis. The NRG1 gene encodes ligands for the ERBB2 (HER2)-ERBB3 heterodimeric receptor tyrosine kinase. Gene fusions of NRG1 such as CD74-NRG1 and SLC33A2-NRG1 have been found at low frequency in a wide range of carcinomas including lung, breast, colorectal, ovarian, and pancreatic cancers and with a wide range of fusion partners.
The present treatment market for advanced tumors with NRG1 fusions comprises chemotherapy and/ or immunotherapy or novel anti-PD-1 agents. Chemotherapy offers a systemic option as a treatment owing to its ability to kill metastasized cancerous cells. Other approaches involve radiation therapy and surgery; however, these only kill the tumor cells located at a single point at a particular time.
In the year 2021, the total incident case of Rare NRG1 Fusion were 5,733 cases in the 7MM which are expected to grow during the study period, i.e., 2019 to 2032. Currently, there are no approved targeted therapies for NRG1 fusions. Standard therapy for advanced tumors harbouring NRG1 fusions remains chemotherapy and/or immunotherapy or novel anti-PD-1 or anti-PD-L1 agents. The problem with utilizing these therapies is that response tends to be suboptimal for patients with NRG1 fusions. The outcomes of preclinical studies have suggested that repurposing FDA-approved HER inhibitors, such as Afatinib (Gilotrif), may have a highly attractive therapeutic strategy for NRG1 fusion-positive tumors. However, RNA sequencing remains the cornerstone of the detection of NRG1 gene fusions owing to higher sensitivity for genetic rearrangements as compared to DNA-based methods, which often do not cover the large introns in NRG1.
MM-121/Seribantumab, Zenocutuzumab/MCLA-128, and HMBD-001 are some promising therapies in the Rare NRG1 fusion pipeline.
Out of all the Rare NRG1 Fusion emerging therapies, Zenocutuzumab is expected to occupy the maximum share of the market owing to novel MoA, efficiency demonstrated in the ongoing trials, and also the early mover advantage. Further, this therapy is in the Phase II stage of clinical development leveraging its competitive advantage.
Currently, a few pharmaceutical companies have indulged themselves in the Rare NRG1 Fusion Market looking at the tremendous potential discovery of the NRG1 fusions are expected to offer. Key pharmaceutical players such as Rain Therapeutics, Elevation Oncology, Merus, Eli Lilly and Company, AVEO Oncology, Hummingbird Bioscience, and several others are evaluating their candidates in different stages of clinical development for the management of Rare NRG1 Fusions.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 9.49 Billion |
| Anticipated Forecast Value (2033) | US$ 20 Billion |
| Projected Growth Rate (2023 to 2033) | CAGR 7.73% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The Rare NRG1 fusion market was valued at US$ 6 Billion in 2018 while growing at a CAGR of 6.61%. Technological advancements in the diagnosis and treatment of various cancers have opened up new prospects for the Rare NRG1 Fusion market which are augmenting market growth.
Further, Standard diagnostic procedures are aiding in market expansion. Considering these new advancements in Oncology, the market for Rare NRG1 Fusion is set to achieve a valuation of USD 20 billion with a CAGR of 7.73% by the end of 2033.
Standard diagnostic protocols to fuel the market expansion
The dynamics of the Rare NRG1 Fusion Market are anticipated to revolutionize in the coming decade owing to the occurrence of such fusions in approximately 0.2% of solid tumors and other invasive tumors. Rare NRG1 Fusion is nothing short of a potential agent for a tumor-agnostic development approach.
Further, the Rare NRG1 Fusion Market is still in its innate state with only a handful of pharmaceutical companies operating in the domain, laying forward immense opportunities for other pharma companies to exploit which will augment the market growth.
Also, standard diagnostic protocols are anticipated to act as a major driver in the steady, smooth growth of the Rare NRG1 Fusion Market size. Additionally, a Rise in the number of research projects for the development of innovative tools and solutions that encourage early detection of tumour-causing mutations is expected to influence substantial growth of the Rare NRG1 Fusion market over the forecast period.
Principal Consultant
Difficulty in conducting clinical trials is holding back growth
The rarity of fusions undoubtedly in itself is a challenge that makes it difficult for researchers to study and conduct clinical trials, and the diversity of NRG1 fusions makes it difficult to diagnose or detect. These concerns are creating challenges for the market expansion of Rare NRG1 Fusion.
The surge in the use of rebuilt diagnostic imaging restricts the market growth
Due to high costs and budgetary constraints, many hospitals in developing nations are not able to invest in diagnostic imaging procedures. However, due to the high demand for diagnostic imaging procedures in these countries, the hospitals that cannot afford to purchase new and advanced imaging systems, prefer to use rebuilt imaging systems. Thus, this factor is a huge challenge for the Rare NRG1 Fusion market growth during the forecast period.
The advent of novel cancer diagnosis methods to fuel the market in Europe
Europe is the fastest-growing region in the Rare NRG1 Fusion market. The increasing incidence of cancer cases in Europe clearly demands early detection and diagnosis of cancer. Researchers are consistently working to discover novel cancer diagnosis methods with minimal invasion. There are approximately 375000 cases of cancers detected each year, with a mortality rate of over 44.1%.
A growing number of researchers, the presence of top-tier research organizations, and pharmaceutical industry giants are all contributing to the advancement of cancer diagnostics research in the UK In addition, the COVID-19 epidemic has significantly increased public awareness of early cancer diagnosis and treatment over the past few years. The market for next-generation cancer diagnostics in the UK is strongly driven by these trends.
On the other hand, the increasing current health expenditure per capita in the European Union, which according to the World Bank, reached US$ 3476.43 (in current US$) in the year 2019, up from US$ 2636.35 in the year 2006, is projected to aid in the growth of Europe RARE NRG1 FUSION market. Besides this, the growing GDP per capita in the European Union is also anticipated to display significant growth opportunities for the Europe RARE NRG1 FUSION market during the forecast period.
Increasing geriatric population opening up new avenues in Japan
The Japan Rare NRG1 Fusion Market is predicted to witness substantial expansion during the forecast period, i.e., 2023 to 2033. The growth of the market can majorly be attributed to the growing geriatric population (aged 65 years or over) in the nation. This growing geriatric population would be in need of advanced healthcare services, which is anticipated to drive the growth of the market in the coming years.
On the other hand, the Japan Rare NRG1 Fusion Market is also poised to grow on account of the numerous opportunities generated by the rising healthcare expenditure by the government of the nation.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Radiation therapy is the most widely used intervention in the Rare NRG1 Fusion market with a segment share of 45%. This segment is expected to grow at a high pace compared to immunotherapy and chemotherapy owing to its high effectiveness and use in primary stages of cancer in killing cancer cells.
Key players in the Rare NRG1 Fusion Market are Elevation Oncology, Merus, Hummingbird Bioscience, Boehringer Ingelheim, CANbridge Pharmaceuticals, Salubris Biotherapeutics, AVEO Oncology, Rain Therapeutics, Eli Lilly and Company, Jiangsu Hengrui Medicine.
Some recent developments in the market are:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 9.49 Billion |
| Market Value in 2033 | US$ 20 Billion |
| Growth Rate | CAGR of 7.73% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
FMI projects the global Rare NRG1 Fusion Market to expand at a 7.73% value CAGR by 2033.
The global Rare NRG1 Fusion Market is expected to garner a market value of US$ 20 billion by 2033.
FMI has projected North America to be one of the most profitable regions for the Rare NRG1 Fusion Market.
Europe is expected to grow fastest during the forecast period.
1. Executive Summary | Rare NRG1 Fusion Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Investment Feasibility Matrix
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2017 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
5.3.1. Chemotherapy
5.3.2. Immunotherapy
5.3.3. Radiation Therapy
5.4. Y-o-Y Growth Trend Analysis By Treatment, 2017 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region
6.1. Introduction
6.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2022
6.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa
6.4. Market Attractiveness Analysis By Region
7. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
7.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
7.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
7.2.1. By Country
7.2.1.1.United States of America
7.2.1.2. Canada
7.2.2. By Treatment
7.3. Market Attractiveness Analysis
7.3.1. By Country
7.3.2. By Treatment
7.4. Key Takeaways
8. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. Brazil
8.2.1.2. Mexico
8.2.1.3. Rest of Latin America
8.2.2. By Treatment
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment
8.4. Key Takeaways
9. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Germany
9.2.1.2. United Kingdom
9.2.1.3. France
9.2.1.4. Spain
9.2.1.5. Italy
9.2.1.6. Russia
9.2.1.7. Rest of Europe
9.2.2. By Treatment
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.4. Key Takeaways
10. Asia Pacific Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. China
10.2.1.2. Japan
10.2.1.3. India
10.2.1.4. South Korea
10.2.1.5. Australia
10.2.1.6. Rest of APAC
10.2.2. By Treatment
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.4. Key Takeaways
11. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. South Africa
11.2.1.2. Saudi Arabia
11.2.1.3. UAE
11.2.1.4. Israel
11.2.1.5. Rest of MEA
11.2.2. By Treatment
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.4. Key Takeaways
12. Key Countries Market Analysis
12.1. United States of America
12.1.1. Pricing Analysis
12.1.2. Market Share Analysis, 2022
12.1.2.1. By Treatment
12.2. Canada
12.2.1. Pricing Analysis
12.2.2. Market Share Analysis, 2022
12.2.2.1. By Treatment
12.3. Brazil
12.3.1. Pricing Analysis
12.3.2. Market Share Analysis, 2022
12.3.2.1. By Treatment
12.4. Mexico
12.4.1. Pricing Analysis
12.4.2. Market Share Analysis, 2022
12.4.2.1. By Treatment
12.5. Germany
12.5.1. Pricing Analysis
12.5.2. Market Share Analysis, 2022
12.5.2.1. By Treatment
12.6. United Kingdom
12.6.1. Pricing Analysis
12.6.2. Market Share Analysis, 2022
12.6.2.1. By Treatment
12.7. France
12.7.1. Pricing Analysis
12.7.2. Market Share Analysis, 2022
12.7.2.1. By Treatment
12.8. Spain
12.8.1. Pricing Analysis
12.8.2. Market Share Analysis, 2022
12.8.2.1. By Treatment
12.9. Italy
12.9.1. Pricing Analysis
12.9.2. Market Share Analysis, 2022
12.9.2.1. By Treatment
12.10. Russia
12.10.1. Pricing Analysis
12.10.2. Market Share Analysis, 2022
12.10.2.1. By Treatment
12.11. China
12.11.1. Pricing Analysis
12.11.2. Market Share Analysis, 2022
12.11.2.1. By Treatment
12.12. Japan
12.12.1. Pricing Analysis
12.12.2. Market Share Analysis, 2022
12.12.2.1. By Treatment
12.13. India
12.13.1. Pricing Analysis
12.13.2. Market Share Analysis, 2022
12.13.2.1. By Treatment
12.14. South Korea
12.14.1. Pricing Analysis
12.14.2. Market Share Analysis, 2022
12.14.2.1. By Treatment
12.15. Australia
12.15.1. Pricing Analysis
12.15.2. Market Share Analysis, 2022
12.15.2.1. By Treatment
12.16. South Africa
12.16.1. Pricing Analysis
12.16.2. Market Share Analysis, 2022
12.16.2.1. By Treatment
12.17. Saudi Arabia
12.17.1. Pricing Analysis
12.17.2. Market Share Analysis, 2022
12.17.2.1. By Treatment
12.18. UAE
12.18.1. Pricing Analysis
12.18.2. Market Share Analysis, 2022
12.18.2.1. By Treatment
12.19. Israel
12.19.1. Pricing Analysis
12.19.2. Market Share Analysis, 2022
12.19.2.1. By Treatment
13. Market Structure Analysis
13.1. Competition Dashboard
13.2. Competition Benchmarking
13.3. Market Share Analysis of Top Players
13.3.1. By Regional
13.3.2. By Treatment
14. Competition Analysis
14.1. Competition Deep Dive
14.1.1. Elevation Oncology
14.1.1.1. Overview
14.1.1.2. Product Portfolio
14.1.1.3. Profitability by Market Segments
14.1.1.4. Sales Footprint
14.1.1.5. Strategy Overview
14.1.1.5.1. Marketing Strategy
14.1.2. Merus
14.1.2.1. Overview
14.1.2.2. Product Portfolio
14.1.2.3. Profitability by Market Segments
14.1.2.4. Sales Footprint
14.1.2.5. Strategy Overview
14.1.2.5.1. Marketing Strategy
14.1.3. Hummingbird Bioscience
14.1.3.1. Overview
14.1.3.2. Product Portfolio
14.1.3.3. Profitability by Market Segments
14.1.3.4. Sales Footprint
14.1.3.5. Strategy Overview
14.1.3.5.1. Marketing Strategy
14.1.4. Boehringer Ingelheim
14.1.4.1. Overview
14.1.4.2. Product Portfolio
14.1.4.3. Profitability by Market Segments
14.1.4.4. Sales Footprint
14.1.4.5. Strategy Overview
14.1.4.5.1. Marketing Strategy
14.1.5. CANbridge Pharmaceuticals
14.1.5.1. Overview
14.1.5.2. Product Portfolio
14.1.5.3. Profitability by Market Segments
14.1.5.4. Sales Footprint
14.1.5.5. Strategy Overview
14.1.5.5.1. Marketing Strategy
14.1.6. Salubris Biotherapeutics
14.1.6.1. Overview
14.1.6.2. Product Portfolio
14.1.6.3. Profitability by Market Segments
14.1.6.4. Sales Footprint
14.1.6.5. Strategy Overview
14.1.6.5.1. Marketing Strategy
14.1.7. AVEO Oncology
14.1.7.1. Overview
14.1.7.2. Product Portfolio
14.1.7.3. Profitability by Market Segments
14.1.7.4. Sales Footprint
14.1.7.5. Strategy Overview
14.1.7.5.1. Marketing Strategy
14.1.8. Rain Therapeutics
14.1.8.1. Overview
14.1.8.2. Product Portfolio
14.1.8.3. Profitability by Market Segments
14.1.8.4. Sales Footprint
14.1.8.5. Strategy Overview
14.1.8.5.1. Marketing Strategy
14.1.9. Eli Lilly and Company
14.1.9.1. Overview
14.1.9.2. Product Portfolio
14.1.9.3. Profitability by Market Segments
14.1.9.4. Sales Footprint
14.1.9.5. Strategy Overview
14.1.9.5.1. Marketing Strategy
14.1.10. Jiangsu Hengrui Medicine
14.1.10.1. Overview
14.1.10.2. Product Portfolio
14.1.10.3. Profitability by Market Segments
14.1.10.4. Sales Footprint
14.1.10.5. Strategy Overview
14.1.10.5.1. Marketing Strategy
15. Assumptions & Acronyms Used
16. Research Methodology
Explore Healthcare Insights
View Reports
Rare NRG1 Fusion Market
